Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHARRD: Ofatumumab vs Rituximab in Relapsed/Refractory DLBCL
NCT01014208Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by GSK. Started Mar 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01014208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014208.